Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Terminated 2Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2

Conditions

Leukemia, Myeloid, Acute 2Leukemia, Promyelocytic, Acute 1

Interventions

Cytarabine 465Cyclophosphamide 459fludarabine phosphate 277Rituximab 249Methotrexate 245Etoposide 203fludarabine 200Filgrastim 199Peripheral Blood Stem Cell Transplantation 180Busulfan 169Vincristine 163Dexamethasone 153Daunorubicin 151Azacitidine 145Mycophenolic Acid 142Whole-Body Irradiation 133Tacrolimus 127Imatinib Mesylate 127Cyclosporine 123Granulocyte Colony-Stimulating Factor 118Radiotherapy 113Melphalan 110Idarubicin 103Doxorubicin 101Mitoxantrone 97Decitabine 97Antilymphocyte Serum 97Lenalidomide 96Mercaptopurine 93Prednisone 91

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × vadastuximab talirine × Other hematologic neoplasm × Clear all
NCT02326584 2018-05-09

A Safety Study of SGN-CD33A in Combination With Standard-of-care in Patients With AML

Seagen Inc.

Phase 1 Completed
116 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT01902329 2018-01-05

A Safety Study of SGN-CD33A in AML Patients

Seagen Inc.

Phase 1 Completed
195 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute, Leukemia, Promyelocytic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡